Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial
In: Journal of Clinical Oncology, Jg. 30 (2012-05-20), S. 552-552
Online
unknown
Zugriff:
552 Background: Use of multi-gene real-time PCR (RT-PCR) based assays e.g. Recurrence Score (RS) and single markers (grade, uPA/PAI-1, ER/PR, HER2, KI-67) is currently controversially discussed in early BC. Here, we present the final WSG-planB trial correlation analysis of risk assessment tools and first prospective comparison of independent central pathology IHC/FISH assessment and RT-PCR for single markers. Methods: Plan B trial (n=2,448 randomized for 6xTC vs. 4xEC-4xDOC in locally HER2- BC). RS has been used as selection criterion for cht omission in HR+ BC (if RS25 (22%). In 354 pN0-1 patients, cht was omitted based on low risk RS (88% compliance). Central grade for n=3038 and IHC/FISH results are currently available in n=1476. Moderately significant correlations were only found between RS and both central grade (rs=0.313; p
Titel: |
Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial
|
---|---|
Autor/in / Beteiligte Person: | Clemens, Michael R. ; Markmann, Susanne ; Liedtke, Bernd ; Krabisch, Petra ; Kreipe, Hans ; Pollmanns, Anke ; Augustin, Doris ; Thomssen, Christoph ; Henschen, S. ; Uleer, Christoph ; Nitz, Ulrike ; Gluz, Oleg ; Harbeck, Nadia ; Liedtke, Cornelia ; Shak, Steven ; Christgen, Matthias ; Aktas, Bahriye ; Kates, Ronald E. ; Salem, Marwa ; Degenhardt, Tom |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 30 (2012-05-20), S. 552-552 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2012 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2012.30.15_suppl.552 |
Schlagwort: |
|
Sonstiges: |
|